Eric Jonasch

22.8k total citations · 2 hit papers
314 papers, 9.2k citations indexed

About

Eric Jonasch is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Eric Jonasch has authored 314 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 241 papers in Pulmonary and Respiratory Medicine, 151 papers in Cancer Research and 148 papers in Molecular Biology. Recurrent topics in Eric Jonasch's work include Renal cell carcinoma treatment (221 papers), Cancer Genomics and Diagnostics (100 papers) and Renal and related cancers (98 papers). Eric Jonasch is often cited by papers focused on Renal cell carcinoma treatment (221 papers), Cancer Genomics and Diagnostics (100 papers) and Renal and related cancers (98 papers). Eric Jonasch collaborates with scholars based in United States, United Kingdom and France. Eric Jonasch's co-authors include Nizar M. Tannir, Christopher G. Wood, Surena F. Matin, W. Kimryn Rathmell, Pheroze Tamboli, Cheryl L. Walker, José A. Karam, Paul G. Corn, Brian I. Rini and Kanishka Sircar and has published in prestigious journals such as Cell, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Eric Jonasch

298 papers receiving 9.0k citations

Hit Papers

High tumor mutation burden fails to predict immune checkp... 2020 2026 2022 2024 2021 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
    2021 672 citations Daniel J. McGrail, Leonie Voorwerk et al. Annals of Oncology profile →
  2. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
    2020 388 citations Eric Jonasch, W. Kimryn Rathmell et al. profile →

Peers

Eric Jonasch
Sergio Bracarda Italy
W. Kimryn Rathmell United States
Wanling Xie United States
Daniel J. George United States
Tomasz Demkow Poland
Jifeng Feng China
Neeraj Agarwal United States
William Kevin Kelly United States
David Olmos United Kingdom
James M. McKiernan United States
Sergio Bracarda Italy
Eric Jonasch
Citations per year, relative to Eric Jonasch Eric Jonasch (= 1×) peers Sergio Bracarda

Countries citing papers authored by Eric Jonasch

Since Specialization
Citations

This map shows the geographic impact of Eric Jonasch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Jonasch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Jonasch more than expected).

Fields of papers citing papers by Eric Jonasch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Jonasch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Jonasch. The network helps show where Eric Jonasch may publish in the future.

Co-authorship network of co-authors of Eric Jonasch

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Jonasch. A scholar is included among the top collaborators of Eric Jonasch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Jonasch. Eric Jonasch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hahn, Andrew W., Nabil Adra, Ulka N. Vaishampayan, et al.. (2025). A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC. The Oncologist. 30(4).
2.
3.
4.
Else, Tobias, Eric Jonasch, Othon Iliopoulos, et al.. (2024). Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study. Clinical Cancer Research. 30(9). 1750–1757. 11 indexed citations
5.
Liu, Xian-De, Yanting Zhang, Daniel J. McGrail, et al.. (2023). SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clinical Cancer Research. 29(19). 4002–4015. 8 indexed citations
6.
Narayan, Vivek, Othon Iliopoulos, Benjamin L. Maughan, et al.. (2023). SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY. Neuro-Oncology Advances. 5(Supplement_3). iii31–iii31. 1 indexed citations
7.
Hahn, Andrew W., Devaki Shilpa Surasi, Tharakeswara Bathala, et al.. (2023). Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. The Oncologist. 29(5). 392–399. 4 indexed citations
8.
Narayan, Vivek & Eric Jonasch. (2022). Systemic Therapy Development in Von Hippel–Lindau Disease: An Outsized Contribution from an Orphan Disease. Cancers. 14(21). 5313–5313. 6 indexed citations
9.
McGuire, Michael H., Santosh K. Dasari, Hui Yao, et al.. (2021). Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling. Molecular Cancer Research. 19(11). 1917–1928. 6 indexed citations
10.
Obradović, Aleksandar, Nivedita Chowdhury, Scott M. Haake, et al.. (2021). Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 184(11). 2988–3005.e16. 191 indexed citations
11.
McGrail, Daniel J., Patrick G. Pilié, Hui Dai, et al.. (2021). Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine. 13(617). eabe6201–eabe6201. 22 indexed citations
12.
Silveira, Henrique C.S., Luis Eduardo Rosa Zucca, Flavio Mavignier Cárcano, et al.. (2021). Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. International Journal of Molecular Sciences. 22(5). 2265–2265. 13 indexed citations
13.
14.
Wiley, Henry E., Hanna R. Coleman, Eric Jonasch, et al.. (2021). Oral HIF-2α inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Investigative Ophthalmology & Visual Science. 62(8). 32–32. 4 indexed citations
15.
Hahn, Andrew W., Omar Alhalabi, Pavlos Msaouel, et al.. (2020). Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 5(6). e001073–e001073. 3 indexed citations
16.
Choueiri, Toni K., Michael B. Atkins, Ziad Bakouny, et al.. (2020). Summary From the First Kidney Cancer Research Summit, September 12–13, 2019: A Focus on Translational Research. JNCI Journal of the National Cancer Institute. 113(3). 234–243. 15 indexed citations
17.
Bergerot, Cristiane Decat, Dena Battle, Errol J. Philip, et al.. (2020). Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice. 16(11). e1264–e1271. 17 indexed citations
18.
Pan, Tianhong, Song-Chang Lin, Kai-Jie Yu, et al.. (2017). BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia. 20(1). 32–43. 15 indexed citations
19.
Griffioen, Arjan W., Annemarie M.A. de Graaf, Patrycja Nowak‐Sliwinska, et al.. (2012). Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients. Clinical Cancer Research. 18(14). 3961–3971. 125 indexed citations
20.
Jonasch, Eric, Christopher G. Wood, Surena F. Matin, et al.. (2009). Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology. 27(25). 4076–4081. 136 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sergio Bracarda Breakdown of academic impact, for papers by W. Kimryn Rathmell Breakdown of academic impact, for papers by Wanling Xie Breakdown of academic impact, for papers by Daniel J. George Breakdown of academic impact, for papers by Tomasz Demkow Breakdown of academic impact, for papers by Jifeng Feng Breakdown of academic impact, for papers by Neeraj Agarwal Breakdown of academic impact, for papers by William Kevin Kelly Breakdown of academic impact, for papers by David Olmos Breakdown of academic impact, for papers by James M. McKiernan
Rankless by CCL
2026